Compare Stocks: EXAS, ARGX, NTRA, and RVMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$872.09 -0.4%	$882.24	$644.63 ▼ $953.58	$54.64B	0.46	346,637 shs	27,326 shs
EXAS Exact Sciences	$104.91	$103.67	$38.81 ▼ $104.98	$20.03B	1.41	3.55 million shs	N/A
NTRA Natera	$312.52 -1.1%	$260.10	$152.62 ▼ $326.03	$45.03B	1.51	1.36 million shs	194,541 shs
RVMD Revolution Medicines	$204.24 -0.5%	$179.60	$35.22 ▼ $208.76	$43.87B	1.39	3.09 million shs	142,555 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.30%	+0.93%	-0.03%	+6.55%	+37.40%
EXAS Exact Sciences	0.00%	0.00%	0.00%	0.00%	+151.34%
NTRA Natera	+1.04%	+15.07%	+15.78%	+60.46%	+97.71%
RVMD Revolution Medicines	-0.14%	+4.03%	+11.58%	+37.33%	+482.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$872.09 -0.4%	$882.24	$644.63 ▼ $953.58	$54.64B	0.46	346,637 shs	27,326 shs
EXAS Exact Sciences	$104.91	$103.67	$38.81 ▼ $104.98	$20.03B	1.41	3.55 million shs	N/A
NTRA Natera	$312.52 -1.1%	$260.10	$152.62 ▼ $326.03	$45.03B	1.51	1.36 million shs	194,541 shs
RVMD Revolution Medicines	$204.24 -0.5%	$179.60	$35.22 ▼ $208.76	$43.87B	1.39	3.09 million shs	142,555 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.30%	+0.93%	-0.03%	+6.55%	+37.40%
EXAS Exact Sciences	0.00%	0.00%	0.00%	0.00%	+151.34%
NTRA Natera	+1.04%	+15.07%	+15.78%	+60.46%	+97.71%
RVMD Revolution Medicines	-0.14%	+4.03%	+11.58%	+37.33%	+482.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,056.89	21.48% Upside
EXAS Exact Sciences	1.95	Reduce	$98.21	-6.38% Downside
NTRA Natera	2.77	Moderate Buy	$316.88	1.00% Upside
RVMD Revolution Medicines	2.91	Moderate Buy	$161.79	-21.08% Downside

Current Analyst Ratings Breakdown

Latest EXAS, ARGX, NTRA, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	NTRA Natera	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$305.00 ➝ $350.00
8/12/2026	NTRA Natera	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$290.00 ➝ $360.00
8/12/2026	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$249.00 ➝ $363.50
8/11/2026	RVMD Revolution Medicines	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$210.00 ➝ $231.00
8/10/2026	NTRA Natera	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$355.00
8/10/2026	RVMD Revolution Medicines	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$220.00
8/7/2026	NTRA Natera	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$325.00 ➝ $340.00
8/7/2026	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$275.00 ➝ $350.00
8/7/2026	NTRA Natera	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$348.00
8/7/2026	NTRA Natera	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$375.00
8/7/2026	NTRA Natera	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$220.00 ➝ $284.00

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	12.81	$21.46 per share	40.54	$134.54 per share	6.47
EXAS Exact Sciences	$3.25B	6.17	$1.27 per share	82.83	$12.58 per share	8.34
NTRA Natera	$2.71B	16.71	N/A	N/A	$12.38 per share	25.34
RVMD Revolution Medicines	$11.58M	3,794.67	N/A	N/A	$12.16 per share	16.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	33.55	23.93	1.07	32.19%	43.59%	36.66%	N/A
EXAS Exact Sciences	-$207.95M	-$1.10	N/A	209.82	2.02	-6.40%	0.53%	0.22%	N/A
NTRA Natera	-$208.16M	-$1.36	N/A	10,458.30	N/A	-7.11%	-11.82%	-8.19%	N/A
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	N/A

Latest EXAS, ARGX, NTRA, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
EXAS Exact Sciences	0.97	2.43	2.17
NTRA Natera	N/A	2.96	2.83
RVMD Revolution Medicines	0.40	11.38	11.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
EXAS Exact Sciences	88.82%
NTRA Natera	99.90%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
EXAS Exact Sciences	1.20%
NTRA Natera	5.05%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
EXAS Exact Sciences	7,200	190.89 million	188.60 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
RVMD Revolution Medicines	250	214.34 million	198.05 million	Optionable

EXAS, ARGX, NTRA, and RVMD Headlines

Recent News About These Companies

Revolution Medicines (RVMD) Receives a Buy from Truist Financial

August 12 at 12:18 PM | theglobeandmail.com

Why Revolution Medicines May Be Big Pharma's Next Takeover Target

August 12 at 8:50 AM | 247wallst.com

Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD

August 12 at 6:31 AM | marketbeat.com

Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD

August 12 at 5:43 AM | marketbeat.com

Revolution Medicines (RVMD) Looks Fairly Valued As BeOne Deal Expands Its Asia Reach

August 12 at 1:31 AM | finance.yahoo.com

Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High - Should You Buy?

August 11 at 3:39 AM | marketbeat.com

Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD

August 11 at 3:20 AM | marketbeat.com

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

August 10 at 6:00 AM | businesswire.com

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

August 9, 2026 | theglobeandmail.com

Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD

August 9, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $240.00

August 9, 2026 | americanbankingnews.com

Sei Investments Co. Cuts Holdings in Revolution Medicines, Inc. $RVMD

August 8, 2026 | marketbeat.com

'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug

August 7, 2026 | bizjournals.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

August 7, 2026 | theglobeandmail.com

High Risk, High Reward: Inside The Revolution Medicines Bull Case

August 7, 2026 | seekingalpha.com

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

August 6, 2026 | zacks.com

Needham & Company LLC Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $240.00

August 6, 2026 | marketbeat.com

Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

August 6, 2026 | marketbeat.com

Revolution Medicines Q2 Earnings Call Highlights

August 5, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results

August 5, 2026 | marketbeat.com

Revolution Medicines Q2 Net Loss Widens

August 5, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EXAS, ARGX, NTRA, and RVMD Company Descriptions

argenex NASDAQ:ARGX

$872.09 -3.91 (-0.45%)

As of 11:23 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Exact Sciences NASDAQ:EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Natera NASDAQ:NTRA

$312.52 -3.44 (-1.09%)

As of 11:24 AM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Revolution Medicines NASDAQ:RVMD

$204.24 -1.02 (-0.50%)

As of 11:24 AM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXAS, ARGX, NTRA, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXAS, ARGX, NTRA, and RVMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXAS, ARGX, NTRA, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EXAS, ARGX, NTRA, and RVMD Company Descriptions

argenex NASDAQ:ARGX

Exact Sciences NASDAQ:EXAS

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EXAS, ARGX, NTRA, and RVMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EXAS, ARGX, NTRA, and RVMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EXAS, ARGX, NTRA, and RVMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EXAS, ARGX, NTRA, and RVMD Company Descriptions

argenex NASDAQ:ARGX

Exact Sciences NASDAQ:EXAS

Natera NASDAQ:NTRA

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools